These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 18451529

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
    Saito M, Kawana J, Ohno T, Hanada K, Kaneko M, Mihara K, Shiomi M, Nagayama M, Sumiyoshi T, Ogata H.
    Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
    Graff DW, Williamson KM, Pieper JA, Carson SW, Adams KF, Cascio WE, Patterson JH.
    J Clin Pharmacol; 2001 Jan; 41(1):97-106. PubMed ID: 11225566
    [Abstract] [Full Text] [Related]

  • 6. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.
    Honda M, Ogura Y, Toyoda W, Taguchi M, Nozawa T, Inoue H, Hashimoto Y.
    Biol Pharm Bull; 2006 Apr; 29(4):772-8. PubMed ID: 16595916
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol.
    Fukumoto K, Kobayashi T, Komamura K, Kamakura S, Kitakaze M, Ueno K.
    Drug Metab Pharmacokinet; 2005 Dec; 20(6):423-7. PubMed ID: 16415527
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
    Nardotto GHB, Lanchote VL, Coelho EB, Della Pasqua O.
    Eur J Pharm Sci; 2017 Nov 15; 109S():S108-S115. PubMed ID: 28522373
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
    Stoschitzky K, Koshucharova G, Zweiker R, Lercher P, Maier R, Klein W, Zitta S, Gruber L, Lamprecht G, Lindner W.
    Cardiovasc Drugs Ther; 2002 Mar 15; 16(2):133-40. PubMed ID: 12090906
    [Abstract] [Full Text] [Related]

  • 16. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
    Nardotto GHB, Coelho EB, Marques MP, Lanchote VL.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar 15; 1015-1016():173-180. PubMed ID: 26927877
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS, Tenero DM, Baidoo CA, Campanile AM, Harter AH, Boyle D, Danoff TM.
    Am J Cardiol; 2006 Oct 02; 98(7A):17L-26L. PubMed ID: 17023228
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.